<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04145674</url>
  </required_header>
  <id_info>
    <org_study_id>NSI-RLS-001</org_study_id>
    <nct_id>NCT04145674</nct_id>
  </id_info>
  <brief_title>A Proof of Concept, Phase 2, Double-blind, Randomized Trial With d-Methadone Product Versus Placebo</brief_title>
  <acronym>Glu-REST</acronym>
  <official_title>A Proof of Concept, Multicentre, Phase 2, Double-Blind, Randomized, Placebo-Controlled Study on the Efficacy, Safety and Tolerability of d-Methadone in Moderate to Very Severe Restless Legs Syndrome With Periodic Limb Movements: the Glu-REST Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mauro Manconi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trial Unit Ente Ospedaliero Cantonale</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ente Ospedaliero Cantonale, Bellinzona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proof of concept, double-blind Randomized Controlled Trial with d-Methadone proposed for the
      first time for use in the treatment of patients diagnosed with primary, moderate to very
      severe RLS. Its glutamatergic mechanism of action might be effective on Restless Legs
      Syndrome arousal pattern and sleep disturbance which highly impair the quality of life of
      Restless Legs Syndrome's patients.

      Patients must take study drug once a day for 10 consecutive days.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2020</start_date>
  <completion_date type="Anticipated">November 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy d-Methadone</measure>
    <time_frame>10 days</time_frame>
    <description>To investigate the efficacy of 10 days of daily dosing with d-Methadone</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Insomnia severity</measure>
    <time_frame>17days</time_frame>
    <description>The change in insomnia severity from baseline (Day 1) to the end of the treatment period (Day 10) will be measured by a using Insomnia Severity Index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life</measure>
    <time_frame>17 days</time_frame>
    <description>Change in quality of life from baseline (Day 1) to the end of the treatment period (Day 10) will be measured by the Restless Legs Syndrome qestionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Periodic limb movements of sleep index</measure>
    <time_frame>10 days</time_frame>
    <description>The change in Periodic limb movements of sleep index from baseline (Day 1) to the end of the treatment period (Day 10) will be measured by means of polysomnography recording</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Actigrafic parameter</measure>
    <time_frame>10 days</time_frame>
    <description>Percentage of total sleep time divided by the time spent in bed</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Restless Legs Syndrome</condition>
  <arm_group>
    <arm_group_label>25 mg d-Methadone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>25 mg d-Methadone Tablet and one 0 mg Placebo Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50 mg d-Methadone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2 x 25 mg d-Methadone Tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 x Non-active substance Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>d-Dextromethadone</intervention_name>
    <description>Patients will take a total of 2 Tablets (one Tablet from each bottle of the kit), once daily at 6 pm over a period of 10 days</description>
    <arm_group_label>25 mg d-Methadone</arm_group_label>
    <arm_group_label>50 mg d-Methadone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will take a total of 2 Tablets (one Tablet from each bottle of the kit), once daily at 6 pm over a period of 10 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary RLS.

          -  Moderate to very severe RLS defined as IRLS-RS score &gt; 10.

          -  PLMS index ≥ 15 as assessed by V-PSG.

          -  Written informed consent.

          -  Willingness and ability to participate in the trial

        Exclusion Criteria:

          -  Positive history of known causes of secondary RLS.

          -  Any other concomitant treatment for RLS (wash-out period: at least 7 days).

          -  Moderate-severe sleep apnea defined as Apnea Hypopnea Index ≥ 15.

          -  History or presence of clinically significant abnormality as assessed by neurological
             examination which in the opinion of the Investigator would jeopardize the safety of
             the patients or the validity of the study results.

          -  Evidence of clinically significant hepatic or renal impairment

          -  History or family history of sudden unexplained death or long QT syndrome.

          -  Any 12-lead ECG with demonstration of QTc ≥ 450 msec or a QRS interval ≥ 120 msec at
             Screening.

          -  Concomitant use of psycho-drugs

          -  History or presence of any condition in which an opioid is contraindicated

          -  History of allergy or hypersensitivity to methadone or related drugs.

          -  Any clinically significant neurological, sleep, hepatic, renal, metabolic,
             hematological, immunological, cardiovascular, pulmonary, chronic pain, psychiatric or
             gastrointestinal disorder.

          -  Women who are pregnant or breast feeding.

          -  Inability to follow the procedures of the study, (e.g. due to language problems,
             psychological disorders, dementia, etc. of the participant).

          -  Previous enrolment into the current study.

          -  Enrolment of the investigator, his/her family members, employees and other dependent
             persons.

          -  Participation in another study with investigational drug within the 30 days preceding
             and during the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mauro Manconi, Prof. MD</last_name>
    <phone>+41 (0)91 811 68 25</phone>
    <email>mauro.manconi@eoc.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jane Frangi</last_name>
    <phone>+41 (0)91 811 6050</phone>
    <email>JaneMarit.Frangi-Kultalahti@eoc.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sleep Center, IRCCS San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Luigi Ferini-Strambi, Prof. DM</last_name>
      <email>ferinistrambi.luigi@hsr.it</email>
    </contact>
    <contact_backup>
      <last_name>Sara Marelli, MD</last_name>
      <email>marelli.sara@hsr.it</email>
    </contact_backup>
    <investigator>
      <last_name>Luigi Ferini-Strambi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sleep Center, Neurocenter of Southern Switzerland</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Mauro Manconi, Prof. MD</last_name>
      <phone>+41 (0)91 811 68 25</phone>
      <email>mauro.manconi@eoc.ch</email>
    </contact>
    <contact_backup>
      <last_name>Jane frangi</last_name>
      <phone>+41 (0)91 811 60 50</phone>
      <email>JaneMarit.Frangi-Kultalahti@eoc.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Mauro Manconi, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epilepsy and Sleep Center, University Hospital Zurich</name>
      <address>
        <city>Zürich</city>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Christian Baumann, Prof. MD</last_name>
      <phone>+41 (0)44 255 88 19</phone>
      <email>christian.baumann@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Baumann, Prof. MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>February 13, 2020</last_update_submitted>
  <last_update_submitted_qc>February 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Ente Ospedaliero Cantonale, Bellinzona</investigator_affiliation>
    <investigator_full_name>Mauro Manconi</investigator_full_name>
    <investigator_title>Prof. MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychomotor Agitation</mesh_term>
    <mesh_term>Restless Legs Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

